Ipsen SA IPN.PA
€161.47 €2.87 (1.81%) 1D
Last Updated: Jun 23, 12:00 AM·XPAR
Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
IPN.PA Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: September 12, 2025
Report Source: 2025 2nd Quarter Report
Ipsen SA. Stock Analysis IPN.PA
France Health Care Large Cap Report: Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. The company employs 5,535 full-time employees The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Read More Ipsen SA (IPN.PA) Chart
Key Statistics of Ipsen SA (IPN.PA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
€158.60Volume
118.91KP/E Ratio (TTM)
29.3152 Week Range
Market Cap
13.20BAvg. Volume
140.08KDividend Yield
0.89%Financial Metrics & Statements of Ipsen SA (IPN.PA)
FAQ's for Ipsen SA (IPN.PA)
- According to Musaffa’s Shariah screening methodology, Ipsen SA (IPN.PA) is currently classified as HALAL as of September 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Ipsen SA using these criteria to determine its compliance status.
- Muslim investors may consider investing in Ipsen SA if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Ipsen SA by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Ipsen SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Ipsen SA on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.